This summary article helps explain the results of Deciphera's Phase 3 INTRIGUE trial as published in Future Medicine, authored by Marina Symcox & Robin L Jones.
Theseus Pharmaceuticals announced yesterday the discontinuation of enrollment in the Phase 1/2 study and terminating the development of THE-630 for GIST patients with advanced or metastatic GIST. The company reported dose-limiting toxicities relating to [...]
These new data were presented by Dr. Sebastian Bauer and Dr. Breelyn A. Wilky during the 2023 January ASCO Plenary Series from the INTRIGUE Efficacy Results of ctDNA Analysis for GIST Patients.
In this summary, we continue highlighting recent clinical trials that are still recruiting in the U.S. which investigate potential treatments for GIST patients.
December 2021 - In this summary, we have highlighted recent clinical trials that are still recruiting in the U.S. which investigate potential treatments for GIST patients.
Dr. David Josephy and Jim Hughes discuss clinical trials for GISTers and what you need to know.
Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.
The FDA approved QINLOCKTM (ripretinib) for the treatment of adults with advanced gastrointestinal stromal tumor (GIST) who have received 3 or more prior treatments for their GIST.
Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST.
The mission of the Clinical Trials Transformation Initiative (CTTI) is to develop and drive the adoption of practices that will increase the quality and efficiency of clinical trials.